whitepaper
Beyond the lab: immuno-oncology
Read this in-depth analyses and insights from leading experts in the field focusing on treatments, new technologies and engineered bacteria.
List view / Grid view
Targets
article
International Day for Women and Girls in Science: Denise Bowser
The International Day for Women and Girls in Science: we have the privilege of engaging with Denise Bowser, a distinguished figure with a remarkable journey at Onyx Scientific. Join us as we explore Denise's experiences, the milestones and challenges she has encountered while navigating the dynamic landscape of the pharmaceutical…
news
New therapeutic targets for stress related disorders
A mechanism by which the immune system influences central nervous system function and behaviour has been discovered.
article
eBook: Reveal Cell Function With Single-Cell Resolution
This eBook explores a new means to perform single-cell functional analysis. Uncover the Xdrop®single-cell format workflow with its ability to help identify, quantify, and comprehend immune cell functions at the individual cellular level.
whitepaper
A Guide to Measuring Drug-Target Residence Times
This guide provides technical background on concepts and techniques for use of Transcreener biochemical assays to measure drug-target residence times.
whitepaper
Whitepaper: Targeting kinases in the innate immune response
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
webinar
Developing next generation non-replicative HSV-1 vectors for sustainable and more precise gene therapies
22 January 2024 | By Drug Target Review, sponsored by Bio Rad Technologies
Watch this webinar to learn how the challenges with using certain viral vectors in gene therapy has advanced the development of a new generation of precise vectors with sustainable effects. Our experts outline the limitations of existing vectors and how these can be overcome using modified recombinant non-replicative herpes simplex…
whitepaper
Case Study: Target discovery for rheumatoid arthritis
Learn more about Euretos computational disease model and how it predicts many of the known drug targets for RA.
article
A Guide to DNA Damage Response and Innate Immunity
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
article
Unique self-activating proteins for drug discovery
Explore cutting-edge hit-to-lead insights through exclusive interviews and studies by leading experts in the field.
article
The future of mRNA biology and AI convergence
In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process. mRNA biology holds immense potential with RNAi drugs in the market and mRNA vaccines showing promise, particularly…
article
Women in Stem with Andrea Pfeifer
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership,…
article
Exploring liver disease therapies
Ochre Bio is at the forefront of therapeutic innovation, focusing primarily on liver diseases. Their core mission revolves around the development of RNA therapies, primarily in the preclinical stage, using a 'human-first' approach. They employ real human tissue, such as 'liver slices' and whole human livers, in their preclinical pipeline…
news
Mitochondria-targeting antibiotics reduce aging in C. elegans
Treating C. elegans with inhibitors of small or large mitochondrial ribosomes extended their median lifespan.
article
The role of STRIs in cancer
Within cancer cells, the eIF4F complex's dysregulation amplifies the translation of cancer-promoting proteins, establishing it as a critical juncture in malignancy and resistance to treatment. eFFECTOR Therapeutics has responded with Selective Translation Regulator Inhibitors (STRIs). These STRIs are precision instruments dismantling the foundations of tumour growth, immune evasion, and resistance…
